| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 15
| Issue : 2 | Page : 169-173 |
|
|
Correlation between non-high-density lipoprotein-cholesterol and the degree of glycemic control in type 2 diabetes mellitus
Abdulazeez Sulaiman Safo
Department of Internal Medicine, College of Medicine, University of Duhok; Department of Internal Medicine, Azadi Teaching Hospital, Duhok City, Dahuk, Iraqi Kurdistan
Correspondence Address:
Abdulazeez Sulaiman Safo
Department of Internal Medicine, College of Medicine, University of Duhok, Dahuk
Iraqi Kurdistan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/MJBL.MJBL_35_18
|
|
|
Backgrounds: Diabetic dyslipidemia is regarded as a modifiable risk factor for cardiovascular diseases (CVDs). Non-high-density lipoprotein-cholesterol (non-HDL-C) is a better measure of CVDs' prediction in contrast with glycosylated hemoglobin (HbA1c) in type 2 diabetic patients. Objectives: In the present study, the prevalence of dyslipidemia and correlation of non-HDL-C with HbA1c were examined and evaluated in patients with type 2 diabetes mellitus. Patients and Methods: In this cross-sectional study, 210 patients aged 18 years and older of both gender previously diagnosed regardless of their sociodemographic characteristics were invited for the assessment of dyslipidemia indicators and HbA1c in Duhok Diabetes Center, Duhok, Iraq, in 2017. Results: The mean age of the study patients was 55.56 (10.48) years and had diabetes for about 7.99 (4.50) years. The study showed a high level of dyslipidemia, including triglyceride, low-density lipoprotein-cholesterol, and non-HDL-C, and low level of HDL-C with a high level of uncontrollable HbA1c. The study revealed a significant positive correlation between HbA1c and non-HDL-C (r = 0.30, P < 0.001). Non-HDL-C was found to be only independent risk factor for higher HbA1c in type 2 diabetic patients (P = 0.002). Conclusions: The present study showed that non-HDL-C can be used as a predictor of HbA1c in type-2 diabetic patients, and its level directly correlated with glycemic control as measured by HbA1c. It is recommended that non-HDL-C to be used by clinicians for routine clinical purposes.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
